公开(公告)号：US11801268B2

公开(公告)日：2023-10-31

申请号：US16084186

申请日：2017-03-14

Applicant: Capricor, Inc.

Inventor： Luis Rodriguez-Borlado ,  Houman Hemmati ,  Jennifer L Johnson ,  Kiel A. Peck ,  Rachel R. Smith ,  Linda Marban

IPC: A61K35/34 ,  A61P27/02 ,  A61K9/00 ,  A61K35/65 ,  A61K35/12

CPC classification number: A61K35/34 ,  A61K9/0014 ,  A61K9/0048 ,  A61K35/12 ,  A61K35/65 ,  A61P27/02

Abstract: The present invention relates to a method of treating a chemical injury of the eye, in particular alkali burn of the cornea, as well as ocular GVHD and similar inflammatory ocular conditions, with extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells. The present invention also provides a formulation comprising extracellular vesicles, in particular exosomes obtained from human cardiospheres or cardiosphere-derived cells, for subconjunctival or topical administration to the eye in the treatment of a chemical injury of the eye, in particular alkali burn of the cornea, as well as ocular GVHD and similar inflammatory ocular conditions.

公开(公告)号：US20230338483A1

公开(公告)日：2023-10-26

申请号：US18042892

申请日：2021-09-03

Applicant: Curebiotech GmbH

Inventor： Ulrich Schraermeyer

IPC: A61K38/57 ,  A61P27/02 ,  A61K38/18 ,  A61K39/395

CPC classification number: A61K38/57 ,  A61P27/02 ,  A61K38/1866 ,  A61K39/3955

Abstract: The present invention is related to a pigment epithelium-derived factor (PEDF) for use in a method for treatment and/or prevention of dry macular degeneration in a subject, preferably dry age-related macular degeneration, wherein the method comprises administering PEDF and VEGF to the subject.

公开(公告)号：US20230338281A1

公开(公告)日：2023-10-26

申请号：US18020544

申请日：2021-09-23

Applicant: OCULAR THERAPEUTIX, INC.

Inventor： Charles D. BLIZZARD ,  Rami EL-HAYEK ,  Michael GOLDSTEIN ,  Peter JARRETT ,  Andrew VANSLETTE

IPC: A61K9/00 ,  A61K9/06 ,  A61K49/00 ,  A61K38/13 ,  A61P27/02

CPC classification number: A61K9/0051 ,  A61K9/06 ,  A61K49/0039 ,  A61K49/0056 ,  A61K38/13 ,  A61P27/02

Abstract: Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

公开(公告)号：US11793798B2

公开(公告)日：2023-10-24

申请号：US17521031

申请日：2021-11-08

Applicant: Santen Pharmaceutical Co., Ltd.

Inventor： Naveed Shams ,  Henk-Andre Kroon ,  Hisashi Kawata ,  Noriko Kawabata

IPC: A61K31/444 ,  A61P27/06 ,  A61P27/02 ,  A61K9/00

CPC classification number: A61K31/444 ,  A61K9/0048 ,  A61P27/02 ,  A61P27/06

Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.

公开(公告)号：US20230330269A1

公开(公告)日：2023-10-19

申请号：US18047255

申请日：2022-10-17

Applicant: HuidaGene Therapeutics Co., Ltd.

Inventor： Shaoran Wang

IPC: A61K48/00 ,  C12N15/86 ,  A61P27/02

CPC classification number: A61K48/0066 ,  C12N15/86 ,  A61P27/02 ,  C12N2750/14143 ,  C12N2750/14145 ,  C12N2750/14171 ,  C12N2750/14122 ,  C12N2830/50

Abstract: The disclosure described herein provides recombinant adeno-associated virus (rAAV) viral particle comprising an AAV9 serotype capsid and a vector genome encoding an RPE65 (e.g., hRPE65) polypeptide, as well as related compositions and uses thereof (e.g., use to treat Leber's congenital amaurosis 2 (LCA2)).

公开(公告)号：US20230322911A1

公开(公告)日：2023-10-12

申请号：US18046112

申请日：2022-10-12

Applicant: Adverum Biotechnologies, Inc.

Inventor： Mark BLUMENKRANZ ,  Mehdi GASMI

IPC: C07K14/005 ,  A61K31/496 ,  C12N15/86 ,  A61K9/10 ,  A61K31/46 ,  A61K39/395 ,  A61K9/00 ,  C07K16/22 ,  A61K48/00 ,  A61P27/02 ,  C12N7/00

CPC classification number: C07K16/22 ,  A61K9/0048 ,  A61K9/10 ,  A61K31/46 ,  A61K31/496 ,  A61K39/3955 ,  A61K48/005 ,  A61K48/0075 ,  A61P27/02 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/76 ,  C12N2750/14122 ,  C12N2750/14143

Abstract: The present disclosure provides pharmaceutical compositions and methods thereof for the prevention or treatment of ocular neovascularization, such as AMD, in a subject, by administering to the subject a pharmaceutical composition comprising a rAAV vector having a nucleic acid sequence that encodes an anti-VEGF agent.

公开(公告)号：US20230310392A1

公开(公告)日：2023-10-05

申请号：US18301510

申请日：2023-04-17

Applicant: Lenz Therapeutics, Inc.

Inventor： Gerald Horn

IPC: A61K31/439 ,  A61K31/498 ,  A61K9/00 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02

CPC classification number: A61K31/439 ,  A61K9/0048 ,  A61K31/498 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02

Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/w of a muscarinic agonist and from about 0.07% to about 0.15% w/w brimonidine.

公开(公告)号：US20230302085A1

公开(公告)日：2023-09-28

申请号：US18021802

申请日：2022-05-16

Applicant: Regeneron Pharmaceuticals, Inc. ,  Bayer HealthCare LLC

Inventor： Robert L. Vitti ,  Alyson J. Berliner ,  Karen Chu ,  Friedrich Asmus ,  Sergio Casimiro da Silva Leal ,  Thomas Eißing ,  Kay D. Rittenhouse

IPC: A61K38/17 ,  A61P27/02

CPC classification number: A61K38/179 ,  A61P27/02

Abstract: The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and extended intervals between doses (e.g., 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower doses such as 2 mg.

公开(公告)号：US20230301984A1

公开(公告)日：2023-09-28

申请号：US18014045

申请日：2021-07-01

Applicant: The USA, as represented by the Secretary, Department of Health and Human Services

Inventor： Anand Swaroop ,  Yu Holly Chen ,  Manju Swaroop ,  Wei Zheng ,  Gregory Tawa ,  Anupam Mondal ,  Samantha Papal ,  Wenwei Huang ,  Zhiji Luo

IPC: A61K31/475 ,  A61K31/473 ,  A61P27/02 ,  A61K31/498

CPC classification number: A61K31/475 ,  A61K31/473 ,  A61K31/498 ,  A61P27/02

Abstract: Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt’s macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.

公开(公告)号：US11766487B2

公开(公告)日：2023-09-26

申请号：US18069347

申请日：2022-12-21

Applicant: 4D MOLECULAR THERAPEUTICS INC.

Inventor： David H. Kirn ,  Melissa Kotterman ,  David Schaffer

IPC: A61K48/00 ,  A61K39/23 ,  C12N15/864 ,  C12N15/02 ,  A61P27/02 ,  A61K9/00 ,  C07K14/005 ,  C12N15/86 ,  C12N15/113

CPC classification number: A61K48/0016 ,  A61K9/0019 ,  A61K9/0048 ,  A61K48/0025 ,  A61K48/0058 ,  A61K48/0075 ,  A61P27/02 ,  C07K14/005 ,  C12N15/113 ,  C12N15/86 ,  C07K2319/00 ,  C12N2750/14122 ,  C12N2750/14143

Abstract: Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.